Press releases
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
- Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
- Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
- Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
- Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
- Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
- Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
- Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
More ▼
Key statistics
As of last trade, Arrowhead Pharmaceuticals Inc (HDP1:MUN) traded at 38.96, 45.64% above the 52 week low of 26.75 set on Jun 17, 2022.
52-week range
Markit short selling activity
Open | 38.96 |
---|---|
High | 38.96 |
Low | 38.96 |
Bid | 39.11 |
Offer | 39.69 |
Previous close | 37.75 |
Average volume | 34.09 |
---|---|
Shares outstanding | 105.74m |
Free float | 102.93m |
P/E (TTM) | -- |
Market cap | 4.23bn USD |
EPS (TTM) | -1.09 USD |
Data delayed at least 15 minutes, as of Jul 07 2022 07:00 BST.
More ▼